Facts about marketingInteresting news
Arena Pharmaceuticals - The Obesity Blockbuster Drug Company and More
By Joseph Dedvukaj - September 18, 2012| Tickers: ARNA, AZN, MRK, PFE| 16
Retail investors were right and Wall Street was wrong about the approval of Arena Pharmaceuticals, Inc's(NASDAQ: ARNA) lead drug candidate Belviq (Lorcaserin). Here are the four coming catalysts for Arena:
1. The Obesity epidemic gives Arena's Belviq blockbuster drug status.
2. The growing obesity market is enormous and Belviq has a broad label.
3. Physicians control the demand for Belviq not the consumer.
4. ARNA is a buyout, merger, or partner candidate.
I believe anyone of these will drive the price of the stock much higher.
My citizen petition filed with the FDA helped ordinary citizens, the FDA, scientists, retail investors, and physicians understand why the FDA must approve Belviq. In my research we saw retail investors fight a bitter battle with Wall Street, with many analysts preoccupied with spreading fear, and heavily shorting the company's stock, hoping to reap the benefits of a company shorted into oblivion. A whopping 43 million shares of Wall Street shorted stock interest still remain trapped turning over and over almost on a daily basis to keep the lid on the stock while institutional investors take their ever increasing positions. Virtually, millions of shares are being traded almost daily, trying to tire and weaken the long investor (the investor who invests because the future is profitable). Steadfastly, we believe Belviq will be a blockbuster drug generating more than $1 billion of revenue for its owner each year. We attempted to school Wall Street financial "wizards" who didn't have the medical expertise to see the fundamentals of the equation here. They ignored our efforts, choosing instead to focus on a competing drug?
Reiterating some of the attempted education:
First, Belviq is a unique single-agent molecule developed using a very innovative high technology called GPCR CART Technology. The FDA correctly approved more than just a new drug candidate for the worst advancing epidemic in U.S. History - Obesity and all the comorbidities that come along with it.
The FDA gave a seal of approval to Arena's proprietary technology that has yielded hundreds of patents as revealed on page 19 of Arena's 2011 annual report. Yes, a promising future for Arena has just begun. We encourage retail investors to hold their winning stock positions in ARNA, and add to positions if possible, because we believe long investors will be handsomely rewarded for patience in this stock. Reading investor message boards on Yahoo, Google and Microsoft can be misleading and often times confusing. The FDA's approval is a testament that Belviq is a super drug because medicines may only be placed on the US market when they are safe, effective and of good quality. This is verified in the new drug authorization process. On June 27, 2012, the FDA approved Belviq for marketing. However, what few investors realize, including Wall Street, is that Belviq also received the very broad label. This usually is more important than the drug approval itself, since drugs can be approved, but with severe label restrictions which restrict use and marketing and therefore revenues.
Additionally, there is not a single documented FDA drug ever that has achieved blockbuster status being sold through mail order. This is NOT the case with Arena, as it is with the competing drug.
Example: VVUS - Qsymia's only marketing technique.
In fact, the very broad label the FDA gave Belviq actually gives physicians, broad discretion in the way a patient's illnesses, diseases, or co-morbidities can be managed with the use of Belviq. The demand for Belviq will come from knowledgeable physicians who have their patient's best interests at heart.